Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Intec Pharma Ltd.    NTEC   IL0011177958

INTEC PHARMA LTD.

(NTEC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Intec Pharma : Says Novartis Ends Development Agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/11/2019 | 08:06am EST

By Colin Kellaher

Intec Pharma Ltd. (NTEC) on Wednesday said Novartis AG (NOVN.EB, NVS) has terminated an agreement for the development of a custom-designed Accordion Pill for a proprietary compound.

The Jerusalem clinical-stage biopharmaceutical company said that although the program met Novartis' technical and pharmacokinetic clinical specifications, the Swiss drug maker decided that it no longer meets its mid- to long-term strategic goals.

Intec said it will receive $1.5 million from Novartis on the conclusion of the program.

Write to Colin Kellaher at colin.kellaher@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
INTEC PHARMA LTD. -4.74% 0.5081 Delayed Quote.-1.88%
NOVARTIS -0.29% 91.94 Delayed Quote.-0.38%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INTEC PHARMA LTD.
2019INTEC PHARMA : Says Novartis Ends Development Agreement
DJ
2019INTEC PHARMA LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2019INTEC PHARMA : to Present at LD Micro's 12th Annual Main Event
AQ
2019INTEC PHARMA LTD. : Entry into a Material Definitive Agreement, Regulation FD Di..
AQ
2019INTEC PHARMA LTD. : Change in Directors or Principal Officers, Submission of Mat..
AQ
2019INTEC PHARMA : Management's Discussion and Analysis of Financial Condition and R..
AQ
2019INTEC PHARMA LTD. : Results of Operations and Financial Condition, Financial Sta..
AQ
2019INTEC PHARMA LTD. : Shareholder Director Nominations (form 8-K)
AQ
2019INTEC PHARMA LTD. : Change in Directors or Principal Officers (form 8-K)
AQ
2019INTEC PHARMA LTD. : Regulation FD Disclosure, Financial Statements and Exhibits ..
AQ
More news
Financials (USD)
Sales 2019 0,38 M
EBIT 2019 -47,1 M
Net income 2019 -47,8 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -0,35x
P/E ratio 2020 -0,86x
Capi. / Sales2019 45,8x
Capi. / Sales2020 infx
Capitalization 17,2 M
Chart INTEC PHARMA LTD.
Duration : Period :
Intec Pharma Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTEC PHARMA LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 0,68  $
Last Close Price 0,49  $
Spread / Highest target 73,3%
Spread / Average Target 37,6%
Spread / Lowest Target 1,92%
EPS Revisions
Managers
NameTitle
Jeffrey A. Meckler Vice Chairman & Chief Executive Officer
John W. Kozarich Chairman
Nadav Navon Chief Operating Officer
Nir Sassi Chief Financial Officer
Anna Hotovely-Salomon Director-Clinical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
INTEC PHARMA LTD.-1.88%17
GILEAD SCIENCES-1.77%80 754
VERTEX PHARMACEUTICALS3.85%58 468
REGENERON PHARMACEUTICALS-8.04%37 106
WUXI APPTEC CO., LTD.3.98%22 682
GENMAB1.55%14 438